We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+17.84%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.95B
AUM Growth
+$102M
Cap. Flow
-$4.3M
Cap. Flow %
-0.11%
Top 10 Hldgs %
61.14%
Holding
68
New
17
Increased
8
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$133M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$99.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$83.8M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$72.8M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$33.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$435M
2
ARGX icon
argenx
ARGX
+$115M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$35.6M
4
SYRE icon
Spyre Therapeutics
SYRE
+$19.1M
5
RVMD icon
Revolution Medicines
RVMD
+$3.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
26
Neumora Therapeutics
NMRA
$311M
$28.5M 0.72%
2,071,450
– –
CLDX icon
27
Celldex Therapeutics
CLDX
$2.79B
$27.3M 0.69%
+650,000
New +$26.7M
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
$27.3M 0.69%
1,999,249
+884,227
+79% +$9.63M
LENZ
29
LENZ Therapeutics
LENZ
$184M
$27.2M 0.69%
1,219,774
-4
-0% -$83
AVIR icon
30
Atea Pharmaceuticals
AVIR
$361M
$24.8M 0.63%
6,145,861
-850,000
-12% -$3.33M
ALEC icon
31
Alector
ALEC
$169M
$24.4M 0.62%
4,056,548
– –
EWTX icon
32
Edgewise Therapeutics
EWTX
$4.34B
$22.8M 0.58%
1,250,385
-2,242,809
-64% -$35.6M
NKTX icon
33
Nkarta
NKTX
$159M
$21.6M 0.55%
+2,000,000
New +$20.8M
PHVS icon
34
Pharvaris
PHVS
$2.35B
$20.8M 0.53%
900,000
– –
PCVX icon
35
Vaxcyte
PCVX
$7.88B
$20.5M 0.52%
+300,000
New +$20.8M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$12.4B
$20M 0.51%
+75,000
New +$17.7M
RNAM
37
DELISTED
Avidity Biosciences
RNAM
$19.3M 0.49%
+757,576
New +$11.9M
OVID icon
38
Ovid Therapeutics
OVID
$440M
$18.7M 0.47%
6,117,400
– –
VERV
39
DELISTED
Verve Therapeutics
VERV
$16.6M 0.42%
1,250,000
– –
KURA icon
40
CALL
Kura Oncology
KURA
$826M
$14.9M 0.38%
+700,000
New +$13.6M
KROS icon
41
Keros Therapeutics
KROS
$199M
$12.4M 0.31%
+187,500
New +$11.1M
DYN icon
42
Dyne Therapeutics
DYN
$4.28B
$12.1M 0.31%
+427,039
New +$9.66M
KYTX icon
43
Kyverna Therapeutics
KYTX
$455M
$11.2M 0.28%
+450,000
New +$12.6M
GOSS icon
44
Gossamer Bio
GOSS
$100M
$10.9M 0.27%
9,195,404
– –
KLRS
45
Kalaris Therapeutics
KLRS
$79.5M
$8.53M 0.22%
+491,069
New +$8.01M
KOD icon
46
Kodiak Sciences
KOD
$2.52B
$8.49M 0.21%
+1,613,600
New +$7.91M
GBIO
47
DELISTED
Generation Bio
GBIO
$8.33M 0.21%
204,687
– –
ATRA icon
48
Atara Biotherapeutics
ATRA
$70.4M
$7.06M 0.18%
406,682
+4,000
+1% +$71K
PRQR icon
49
ProQR Therapeutics
PRQR
$248M
$6.6M 0.17%
2,884,357
-95,659
-3% -$205K
ALGS icon
50
Aligos Therapeutics
ALGS
$26.3M
$6.26M 0.16%
255,579
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2024 Portfolio in Review

As of Q1 2024, EcoR1 Capital held 68 positions worth $3.95B, up 2.7% from $3.85B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q1 2024 filing shows 17 new, 8 increased, 4 reduced and 9 closed positions. Its largest new stake was CRISPR Therapeutics: 1,389,276 shares worth $94.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $435M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • EcoR1 Capital's largest Q1 2024 buy was CRISPR Therapeutics: 1,389,276 shares worth $94.7M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2024, an estimated $133M increase.
  • EcoR1 Capital's biggest Q1 2024 reduction was Edgewise Therapeutics, cutting an estimated $35.6M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $435M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.95B portfolio in Q1 2024.
  • EcoR1 Capital opened 17 new positions and closed 9 in Q1 2024.
  • EcoR1 Capital's portfolio value rose 2.7% quarter-over-quarter to $3.95B.

Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.